💥 Fed cuts sparks mid cap boom! ProPicks AI scores with 4 stocks +23% each. Get October’s update first.Pick Stocks with AI

U.S. to select 10 costliest drugs for Medicare pricing negotiation

Published 02/17/2023, 02:44 PM
Updated 02/17/2023, 02:46 PM
© Reuters. FILE PHOTO: U.S. President Joe Biden delivers remarks on Social Security and Medicare at the University of Tampa in Tampa, Florida, U.S. February 9, 2023. REUTERS/Jonathan Ernst

By Ahmed Aboulenein

WASHINGTON (Reuters) - The U.S. government will select the 10 costliest prescription medicines to Medicare for negotiating prices with drugmakers starting early next year, the program's top official said on Friday.

President Joe Biden in August signed into law the Inflation Reduction Act, allowing the federal Medicare health plan for people age 65 and older and the disabled to negotiate prices on some of its most costly drugs.

The law grants the government the right to choose any 10 from a list of the 50 medicines responsible for the highest Medicare spending that qualify for negotiation, but does not specify the exact criteria for choosing them.

Dr. Meena Seshamani, director of the Center for Medicare, outlined in an interview how Medicare will select the initial drugs for negotiation after first determining which medicines are eligible and not subject to one of several exemptions outlined in the law.

"Then from there, we rank the negotiation-eligible drugs according to total expenditures for that 12-month period, and we will select drugs with the highest ranking," Seshamani said.

To produce that list, the agency first needs to decide whether to use gross Medicare spending or net spending, which takes into account often sizeable after-market discounts.

Seshamani did not comment on which way the agency was leaning, but pointed to a proposed rule published in December in which the Centers for Medicare and Medicaid Services (CMS), which oversees Medicare, redefines the term "gross covered prescription drug costs" within Medicare Part D.

© Reuters. FILE PHOTO: U.S. President Joe Biden delivers remarks on Social Security and Medicare at the University of Tampa in Tampa, Florida, U.S. February 9, 2023. REUTERS/Jonathan Ernst

"We have proposed a clarification to maintain better consistency with gross expenditures. So that is a proposal that is out there, and the comment period closed on February 13," Seshamani said. "We are processing those comments as we work to finalize that regulation."

CMS said in January it would announce the list of 10 drugs in September. The agency will make its initial offers in February 2024 and the negotiation period will end that Aug. 1. It will publish the final prices a month later, and they will take effect on Jan. 1, 2026.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.